SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors upcoming FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with traders focused on the November 22 target date and the companys amended application emphasizing upper-limb function data. Bullish traders interpret the longer-term data, rare-disease policy discussions and recent commercial hiring as encouraging signs, while skeptics cite prior FDA concerns and say approval remains uncertain.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCath reimbursement could fall after early 2027 has fueled a sharp selloff and concern about future pricing and revenue. Traders disagree over whether the warning signals sustained pressure or is only a preliminary estimate, pointing to CMSs more stable outlook while criticizing CorMedixs lack of clarification.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

The rally toward fresh highs is drawing attention ahead of the expected Q3 report, with traders weighing BRIUMVIs growth against unconfirmed buyout speculation and possible short-covering. Some see the move as a bet on earnings and the companys commercial prospects rather than an acquisition; no deal has been confirmed.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLASs REGAL Phase 3 AML trial reaching its prespecified 80th death event has triggered final analysis, with topline results expected this quarter. Traders are divided over whether GPS improved survival: bullish holders see the pending readout as a major catalyst, while bears question the efficacy case, and the share-price decline has intensified debate about selling pressure and alleged short activity.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention after a sharp Nasdaq selloff tied to weakness in technology and semiconductor stocks, with traders debating whether concerns about AI spending and earnings justify more downside or whether the decline is an oversold dip to buy. The late-session rebound prompted some dip-buying optimism, but bearish traders continued to warn that the correction may not be over.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 76,874.98691422 USD and is down -4.82 over the last 24 hours. It is currently trading on 12773 active market(s) with $58,826,736,014.03 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

A reported major Binance security breach and temporary withdrawal suspension have fueled Bitcoin selling and concerns about crypto exchange security. Traders disagree over whether the incident signals broader risk or is isolated to Binance, with some viewing the pullback as a buying opportunity and others warning of further downside.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens PAPZIMEOS commercial launch and stronger-than-expected quarterly results, including a move to profitability, are driving bullish discussion about its growth prospects. Traders also debate whether potential INO-3107 competition could challenge PAPZIMEOS and whether heavy short interest is amplifying the stocks moves.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is caught in a broader technology and semiconductor selloff as traders question whether massive AI infrastructure spending will generate adequate returns, with mixed Amazon and Intel results adding to sector concerns. The community is split between warnings that the AI trade may be overstretched and dip buyers who view the decline as a temporary pullback while AI demand remains strong.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

A strong third-quarter earnings beat, supported by growth in Eylea HD and Sanofi collaboration revenue tied to Dupixent, has driven a sharp move higher in REGN. Traders are broadly cheering the results and breakout, while some are watching for a pullback after the rally.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff ahead of its quarterly report is fueling concern about slowing ad growth, analyst target cuts, and weakness across advertising-related stocks. Traders debate whether the decline reflects deteriorating prospects or has overshot the companys growth and cash-generation fundamentals, with earnings seen as a key test.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HUM Stock Soars, ALHC Sinks As CMS Star Ratings Redraw 2028 Bonuses

Equity

Humana’s largest Medicare Advantage contract, covering more than 2 million members, rose from 3.5 stars to 4, putting it back above the bonus threshold.


ALHC Stock Tumbles After ‘Don’t Poke the Bear’ Silence On Star Ratings — CLOV Falls With It

The Medicare Advantage insurer had already faced skepticism after its second-quarter report. Tuesday’s comments reinforced that picture.


CLOV Stock Hits Over 2-Month High As Humana Deal Buzz Builds Ahead Of Investor Conferences 

Humana listed Counterpart Health among the vendors for its provider-performance and quality programs.

A Court Order Sent CLOV Stock To Over 4.5-Year Highs – Retail Says The Implications Could Be Industry-Wide

A District Court in Georgia ordered the Centers for Medicare & Medicaid Services to recalculate Clover’s 2026 Medicare star rating, following which it was raised to 4.5 from 3.5

Caseys General Stores Upbeat Q4 Earnings, Joins Applied Optoelectronics, Clover Health Investments And Other Big Stocks Moving Higher On Wednesday

US stocks down, Dow Jones fell 150 pts on Wed. Caseys General Stores Inc (CASY) shares up 14.4% after beating earnings. Other big gainers incl. CBRL, PLBL, RXT, YB, AXTI, AAOI, LMND, CLOV, TGTX, CRDO, CBRS, HOOD, FLNC, LITE, TTMIread more...

Clover Health Q1 Earnings Meet Estimates, Sales Beat, Membership Rises

CLOV posts 62% revenue growth in Q1 as Medicare Advantage membership surges and AI-driven care initiatives boost profitability.

Clover Health Investments (NASDAQ:CLOV) Releases Earnings Results, Misses Estimates By $0.02 EPS

Clover Health Investments (NASDAQ:CLOV - Get Free Report) issued its quarterly earnings results on Wednesday. The company reported $0.05 EPS for the quarter, missing the consensus estimate of $0.07 by ($0.02). Clover Health Investments had a negative return on equity of 25.17% and a negative net...

Clover Health Investments Q1 Earnings Call Highlights

Clover Health Investments (NASDAQ:CLOV) reported first-quarter 2026 results that management said demonstrated the ability to combine rapid Medicare Advantage growth with GAAP profitability as the company continues scaling its technology-driven care model.

Membership growth and GAAP profitability
Ch...

Clover Health Investments, Corp. (CLOV) Meets Q1 Earnings Estimates

Clover Health Investments (CLOV) delivered earnings and revenue surprises of 0.00% and +5.85%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Butterfly Network, Inc. (BFLY) Reports Q1 Loss, Beats Revenue Estimates

Butterfly Network (BFLY) delivered earnings and revenue surprises of +25.00% and +2.04%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Clover Health Investments Corp. is a physician enablement technology company, which engages in the provision of Medicare Advantage plans in the United States. Its strategy is powered by its proprietary software platform, Clover Assistant, which aggregates patient data from across the healthcare ecosystem to support clinical decision-making and improve health outcomes through the early identification and management of chronic diseases. The company offers PPO and HMO Medicare Advantage plans in several states, with a differentiated focus on its flagship wide-network, high-choice PPO plans. The company was founded by Vivek Garipalli and Andrew Toy on July 17, 2014 and is headquartered in Wilmington, DE.

Clover Health Investments Corp - Ordinary Shares - Class A

Bearish Sentiment

<ul class="summary-bullets"><li>Alignment Healthcare’s largest California contract, H3815, fell from 4 stars to 3.5.</li><li>Aetna said more than 69% of its Medicare Advantage members are in 2027 plans rated 4 stars or higher, and President Steve Nelson said the results “highlight our distinction in the market.”</li><li>Crossing 4 on CMS star rating unlocks bonus payments that raise the federal money an insurer receives per member.</li></ul><p>Humana (HUM) shares surged as much as 13% in after-hours trading Thursday after the Centers for Medicare &amp; Medicaid Services released 2027 Medicare Advantage star ratings, a quality scorecard that decides which plans earn extra federal bonus payments, while Alignment Healthcare (ALHC) tumbled 23% after its largest contract fell below that cutoff.</p><p>CVS Health fell about 3% in extended trading, and Clover Health rose about 10%.</p><h2 class="st-heading-2">Why The Stars Move The Stocks</h2><p>Medicare Advantage is the private version of Medicare. CMS scores each contract from 1 to 5 stars on measures such as clinical outcomes, member experience, and how the plan is run. The 4-star mark is the cutoff that matters to investors. Crossing it unlocks bonus payments that raise the federal money an insurer receives per member. Dropping below it takes that bonus away.</p><p>The ratings published Thursday do not change this year’s results. They feed payments in 2028, which is why a single half-star move on a large contract can be worth hundreds of millions of dollars.</p><h2 class="st-heading-2">Humana Clears The Bonus Line</h2><p>Humana was the clearest winner. Its largest Medicare Advantage contract, covering more than 2 million members, rose from 3.5 stars to 4, putting it back above the bonus threshold, CMS data showed.</p><p>The rebound matters because Humana was hit hard the last time CMS published ratings. In October 2024, the share of its members in plans rated 4 stars or higher fell from 94% to 25%, after a large contract dropped from 4.5 stars to 3.5. That cut the bonus payments the company was set to receive in 2026. Thursday’s recovery puts that large contract back in line for bonuses in 2028.</p><h2 class="st-heading-2">Alignment And CVS Lose Ground</h2><p>Alignment Healthcare moved the other way. Its largest California contract, H3815, fell from 4 stars to 3.5. That contract accounted for about 81% of membership, so the downgrade knocked most of the company off the bonus list even though six of its seven rated contracts still scored 4 stars or higher, including three at 4.5. Dawn Maroney, president of Alignment Health, said the California rating “is inconsistent with that performance” and that the company “intend[s] to pursue all available administrative remedies and to litigate the measures and methodologies we believe warrant review,” while remaining confident it can return the contract to at least 4 stars.</p><p>CVS, through its Aetna unit, also lost ground. Aetna said more than 69% of its Medicare Advantage members are in 2027 plans rated 4 stars or higher, and President Steve Nelson said the results “highlight our distinction in the market” and give the company confidence it can return to “appropriate margins.” The smaller stock move reflected a broader book than Alignment’s, so a slip on part of it does not rewrite the whole company’s 2028 revenue.</p><p>Clover Health said CMS gave the plans covering about 98% of its members a 5-star rating for 2027, the score that sets 2028 payments. A smaller plan scored 4.5 stars. The 5-star score leaves out 20 measures a federal judge told CMS not to count in a May ruling that the agency has appealed. With those measures included, Clover said, the larger plans would have scored 4.5 stars.</p><h2 class="st-heading-2">How Did Retail Traders React?</h2><p>On Stocktwits, retail sentiment around HUM and ALHC was 'bullish' at the time of writing.</p><p>While <a class="mention" data-mention="$HUM" data-symbol-id="HUM" href="https://stocktwits.com/symbol/HUM" target="_blank">HUM stock</a> has gained 51% year-to-date, CVS added 11%, and CLOV 95%. ALHC, in the meantime, has fallen 56%</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/t-tmus-vz-stocks-plunge-after-hours-as-space-x-buys-800-m-hz-spectrum-for-starlink-mobile/cZDUxmJRBV5">T, TMUS, VZ Stocks Plunge After-Hours As SpaceX Buys 800 MHz Spectrum For Starlink Mobile</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

 Stethoscope with medicare form with parts list. Source: Getty Images

Humana’s largest Medicare Advantage contract, covering more than 2 million members, rose from 3.5 stars to 4, putting it back above the bonus threshold.

Alignment Healthcare Inc

Clover Health Investments Corp

CVS Health Corp

Humana Inc

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$4.46
Prev Close	$4.58
Open	$4.53
Dividend Yield	0.00%
50-Day Moving Average	$4.50
Beta	1.10
Avg. Volume	4.11M
PE Ratio	-113.93

52-Week High	$5.59
52-Week Low	$1.58
Market Capitalization	$2.43B
EPS (Annual)	-$0.1671
Price to Book	6.01
Revenue Per Employee	$2.66M

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLOV Fundamentals